Related Experiment Video
Updated: May 13, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Tumor agnostic drug delivery with dynamic nanohydrogels
Stephen N Housley1,2,3,4, Alisyn R Bourque5,6, Lilya V Matyunina7
1School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA. nickhousley@gatech.edu.
Abstract:
RNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-specific manner. However, systemic delivery of RNAi to tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that significantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the first direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell- or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.
Insights
This study introduces self-agglomerating nanohydrogels (SANGs) for effective RNA interference (RNAi) cancer therapy. SANGs deliver RNAi payloads to tumors, suppressing oncogenes and sensitizing resistant cancers with demonstrated safety.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- RNA interference (RNAi) offers targeted oncogene regulation but faces significant delivery challenges in cancer therapy.
- Existing RNAi delivery strategies have shown limited clinical translation due to systemic obstructions and poor tumor localization.
- Developing effective and safe delivery systems is crucial for realizing the therapeutic potential of RNAi in oncology.
Purpose of the Study:
- To develop a novel nanohydrogel platform (SANGs) for efficient and selective delivery of RNAi payloads to solid tumors.
- To investigate the tumor-homing, cellular internalization, and payload-agnostic capabilities of the SANGs platform.
- To evaluate the therapeutic efficacy, safety, and underlying delivery mechanism of SANGs in preclinical cancer models.
Main Methods:
- Development of self-agglomerating nanohydrogels (SANGs) capable of carrying multiple RNAi payloads.
- Intravenous administration of SANGs in rodent models of aggressive cancers to assess tumor accumulation and retention.
- Evaluation of oncogene suppression, tumor sensitization to therapy, and safety profiles in simulated clinical applications across multiple species.
Main Results:
- SANGs demonstrated preferential accumulation and durable retention in primary and metastatic tumor sites across four aggressive cancer models.
- The SANGs platform successfully delivered multiple RNAi payloads, leading to significant oncogene expression suppression.
- Treated tumors showed sensitization to therapies, and SANGs exhibited a favorable safety profile in preclinical species, indicating potential for clinical use.
Conclusions:
- The SANGs platform provides an enabling technology for RNAi-based cancer therapeutics, overcoming key delivery barriers.
- Emergent material properties of SANGs facilitate durable solid-tumor delivery without the need for specific targeting ligands.
- SANGs are poised for advanced pharmaceutical development for treating multiple solid-tumor indications.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers